Natco Pharma.
Indian pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 13
What's happening
Active this week
Earlier this month
One to three months ago
-
Natco Pharma produced a generic version of a Bayer drug, while Akshaya expanded its network in Kerala.Some support1 report
-
Natco Pharma and Bonus were identified as dividend payers in the market.Some support1 report
-
Natco Pharma and Novartis are challenging patent exclusivity of the drug ribociclib in the Delhi High Court.Some support1 report
-
FDA granted tentative approval for Olaparib tablets, manufactured by Natco Pharma, which are bioequivalent to Lynparza.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Natco Pharma this week
News at the entities that move Natco Pharma most-
Novartis OperationalNovartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Moves Natco Pharma
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Natco Pharma
-
Delhi High Court OperationalHigh Court operations were noted within the city of Delhi on May 18, 2026.Moves Natco Pharma
-
AstraZeneca OperationalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Natco Pharma
-
BAYER OperationalBayer is supplying canola feedstock to Neste to jointly scale winter canola for biofuels.Moves Natco Pharma
-
RSI Mentioned togetherTrump's pledge to unleash oil and gas is reported to benefit stocks, involving Landstar System.Moves Natco Pharma
Connections
The 8 strongest of 13, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Operational
The two companies are engaged in direct market competition regarding the patent exclusivity of the drug ribociclib.
-
FDA Structural
The FDA, as the regulatory body, granted tentative approval for Olaparib tablets, directly impacting Natco Pharma's product lifecycle.
-
AstraZeneca Operational
Natco manufactures a bioequivalent version of Olaparib to AstraZeneca's Lynparza, establishing direct market competition.
-
BAYER Operational
Natco Pharma produces generic versions of Bayer's drugs, establishing a direct market competition based on the original product.
-
Delhi High Court Operational
Natco Pharma is actively petitioning the Delhi High Court regarding patent office decisions.
-
Bonus Mentioned together
Both entities are noted as dividend payers in the market.
-
RSI Mentioned together
No direct relationship between the two entities is established in the provided evidence.
-
India Mentioned together
No evidence provided in the timeline to determine the relationship between India and Natco Pharma.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
4 events- India and Natco Pharma are investing in the U.S. biotech company eGenesis.
- Natco Pharma produced a generic version of a Bayer drug, while Akshaya expanded its network in Kerala.
- Natco Pharma and Bonus were identified as dividend payers in the market.
- Natco Pharma and Novartis are challenging patent exclusivity of the drug ribociclib in the Delhi High Court.